Locations
London, UK · Mile End, London, UK · Kingston Vale, London SW15, UK
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series C+
founded in
2013
Pulmocide is a biopharmaceutical company focused on developing novel inhaled therapies for serious respiratory diseases, particularly targeting difficult-to-treat fungal infections like invasive pulmonary aspergillosis. Their lead compound, opelconazole, is currently in a Phase 3 clinical trial aimed at patients who do not respond to existing antifungal treatments. The company differentiates itself through its innovative drug design that allows for high concentrations of medication to reach the lungs while minimizing systemic exposure, thereby improving patient outcomes and reducing side effects. With a strong leadership team experienced in drug development and a clear focus on addressing significant unmet medical needs, Pulmocide is well-positioned in the biopharmaceutical market.
Something looks off?